Replimune Highlights RP1, RP2 Progress Ahead of JPM Conference

Replimune Group ( (REPL) ) has shared an announcement.

On January 12, 2026, Replimune released an updated corporate presentation highlighting recent strategic developments and clinical data for its RP1 and RP2 oncolytic immunotherapy programs ahead of its appearance at the J.P. Morgan Healthcare Conference on January 14, 2026. The company reported that it is preparing for a potential commercial launch in melanoma, with a near-term regulatory decision date of April 10, 2026, a “launch ready” commercial team, and roughly 150 treatment accounts expected to be activated on day one, reflecting significant operational build-out. Clinical data from the IGNYTE study in anti-PD-1–failed melanoma showed durable and clinically meaningful response rates across difficult, resistant patient subgroups, with approximately 1,000 patients treated across the RPx platform and successful administration into deep lesions such as liver and lung, underscoring the platform’s potential to address resistance to checkpoint inhibitors and support Replimune’s competitive positioning in the immuno-oncology field.

The most recent analyst rating on (REPL) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Replimune Group stock, see the REPL Stock Forecast page.

Spark’s Take on REPL Stock

According to Spark, TipRanks’ AI Analyst, REPL is a Neutral.

The score is held down primarily by weak financial performance (no meaningful revenue, widening losses, and heavy cash burn) and a loss-driven valuation profile (negative P/E, no dividend). Offsetting these are moderately supportive longer-term technicals and a meaningful positive corporate catalyst from the FDA’s acceptance of the RP1 resubmission and PDUFA date.

To see Spark’s full report on REPL stock, click here.

More about Replimune Group

Replimune Group, Inc. is a biotechnology company focused on developing oncolytic immunotherapies designed to ignite systemic immune responses against cancer. Its RPx platform, including lead candidates RP1 and RP2, targets both superficial and deep or visceral tumors, with a growing body of clinical experience in melanoma and expansion into hard-to-treat indications such as hepatocellular carcinoma and biliary tract cancer, positioning the company within the immuno-oncology segment of the cancer therapeutics market.

Average Trading Volume: 3,962,687

Technical Sentiment Signal: Sell

Current Market Cap: $645.6M

For an in-depth examination of REPL stock, go to TipRanks’ Overview page.